

DAFTAR PUSTAKA

- Andriana, A., Prasetya, A. T., dan Harjito, H., 2013, pengaruh enkapsulasi logam Ga dan As terhadap celah pita boron nitride nanotube (4, 4), *Indones. J. Chem.*, 2(1), 18-23.
- Anonim, 2002, *National cancer control programmes: policies and managerial guidelines*, World Health Organization, Geneva.
- Anonim, 2017, *Breast cancer treatment guideline*, American Cancer Society, Atlanta.
- Awasthi, S. K., Mishra, N., Kumar, B., Sharma, M., Battacharya, A., Mishra, L. C. and Bhasin, V. K., 2009, Potent antimalarial activity of newly synthesized substituted chalcone analog in vitro, *Med. Chem. Res.*, 18, 407–420.
- Baghel, S. S., Shrivastava, N., Baghel, R. S., Agrawal, P., and Rajput, S., 2012, A review of quercetin: antioxidant and anticancer properties, *World J. Pharm. Sci.*, 1(1), 146-60.
- Balgoname, A. A., Alomair, S. M., AlMubirek, A. K., and Khedr, M. A., 2021, Fragment-based discovery of potential anticancer lead: computational and in vitro studies, *Curr. Comput. Aided Drug Des.*, 17(3), 421-428.
- Baselga, J., 2002, Why the epidermal growth factor receptor? The rationale for cancer therapy, *Oncologist*, 7(4), 2–8.
- Biova, D. S., 2017, *Discovery studio 2017*, Dassault Systèmes, San Diego.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A., 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA Cancer J. Clin.*, 68(6), 394–424.
- Chaudhary, K.K., and Mishra, N., 2016, A review on molecular docking: novel tool for drug discovery, *JSM. Chem.*, 4(3), 1-4.
- Chen, Y., Luo, Y., Wu, C., Lee, Y., Perng, R., and Whang-peng, J., 2015, Erlotinib or chemotherapy in second-line or later treatment of tumor EGFR wild-type pulmonary adenocarcinoma patients, *J. Cancer Res. Pract.*, 2(1), 3–11.
- Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. A., Miller, A.H., Payne, R., Reuben, J.M., Wang, X.S., and Lee, B. N., 2003, Are the symptoms of cancer and cancer treatment due to a shared biologic

mechanism? A cytokine-immunologic model of cancer symptoms, *Cancer*, 97(11), 2919-2925.

Cosconati, S., Forli, S., Perryman, A. L., Harris, R., Goodsell, D. S., and Olson, A. J., 2010, Virtual screening with AutoDock: theory and practice, *Expert Opin. Drug Discov.*, 5(6), 597-607.

Davis, J. M., Navolanic, P. M., WeinsteinOppenheimer, C. R., Steelman, L.S., Wei, H., Konopleva, M., Blagosklonny, M. V., and McCubrey, J. A., 2003, Raf-1 and Bcl-2 Induce distinct and common pathways that contribute to breast cancer drug resistance, *Clin. Cancer Res.*, 9, 1161-1170.

Doroshov, J. H., 2020, Effect of anticancer quinones on reactive oxygen production by adult rat heart myocytes, *Oxid. Med. Cell Longev.*, 2020, 1-7.

Fathi, E. M., Sroor, F. M., Mahrous, K. F., Mohamed, M. F., Mahmoud, K., Emara, M., Elwahy, A.H.M., and Abdelhamid, I. A., 2021, Design, synthesis, in silico and in vitro anticancer activity of novel bis-furanyl-chalcone derivatives linked through alkyl spacers, *ChemistrySelect*, 6(24), 6202–6211.

Franklin, Matthew C., Kendall D. Carey, Felix F. Vajdos, Daniel J. Leahy, Abraham M. De Vos, and Mark X. Sliwkowski, 2004, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, *Cancer cell*, 5(4), 317-328.

Gaillard, T., 2018, Evaluation of AutoDock and AutoDock Vina on the CASF-2013 benchmark, *J. Chem. Inf. Model.*, 58(8), 1697-1706.

Gupta, D., and Jain, D. K., 2015, Chalcone derivatives as potential antifungal agents: Synthesis, and antifungal activity, *J. Adv. Pharm. Technol. Res.*, 6(3), 114-117.

Huarte, M., 2015, The emerging role of lncRNAs in cancer, *Nat. Med.*, 21(11), 1253–1261.

Hussain, W., Amir, A., and Rasool, N., 2020, Computer-aided study of selective flavonoids against chikungunya virus replication using molecular docking and DFT-based approach, *Struct. Chem.*, 1-12.

Iqbal, N., and Iqbal, N., 2014, Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications, *Mol. Biol. Int.*, 2014, 1-9.

- Jayapal, M. R., Prasad, K. S. and Sreedhar, N. Y., 2010, synthesis and characterization of 2,5-dihydroxy substituted chalcones using $\text{SOCl}_2/\text{EtOH}$, *Int. J. Pharm. Pharm. Sci*, 1, 361-366.
- Karthikeyan, C., SH Narayana Moorthy, N., Ramasamy, S., Vanam, U., Manivannan, E., Karunakaran, D., and Trivedi, P., 2015, Advances in chalcones with anticancer activities, *Recent Pat. Anticancer Drug Discov.*, 10(1), 97-115.
- King, R. J. B., 2000, *Cancer biology (2nd ed.)*, Pearson Education, London.
- Koudokpon, H., Armstrong, N., Dougnon, T. V., Fah, L., Hounsa, E., Bankolé, H. S., Loko, F., Chabiére, E. and Rolain, J. M., 2018, Antibacterial activity of chalcone and dihydrochalcone compounds from *Uvaria chamae* roots against multidrug-resistant bacteria, *BioMed. Res. Int.*, 2018, 1-10.
- Kovačević, S. Z., Podunavac-Kuzmanović, S. O., Jevrić, L. R., Vukić, V. R., Savić, M. P., and Djurendić, E. A., 2016, Preselection of A- and B- modified d-homo lactone and d-seco androstane derivatives as potent compounds with antiproliferative activity against breast and prostate cancer cells – QSAR approach and molecular docking analysis, *Eur. J. Pharm. Sci.*, 93, 107–113.
- Lahsasni, S. A., Al Korbi, F.H. and Aljaber, N. A. A., 2014, Synthesis, characterization, and evaluation of antioxidant activities of some novel chalcones analogues, *Chem. Cent. J.*, 8, 1-10
- Maria, K., Dimitra, H. L. and Maria, G., 2008, Synthesis and anti-inflammatory activity of chalcones and related Mannich bases, *Med. Chem.*, 4(6), 586-596.
- Mena-Ulecia, K., Tiznado, W., and Caballero, J., 2015, Study of the differential activity of thrombin inhibitors using docking, QSAR, molecular dynamics, and MM-GBSA, *PLoS. One.*, 10(11), e0142774.
- Modzelewska, A., Pettit, C., Achanta, G., Davidson, N. E., Huang, P., and Khan, S. R., 2006, Anticancer activities of novel chalcone and bis-chalcone derivatives, *Bioorg. Med. Chem.*, 14(10), 3491-3495.
- Nakayama, A., Takagi, S., Yusa, T., Yaguchi, M., Hayashi, A., Tamura, T., Kawakita, Y., Ishikawa, T., and Ohta, Y., 2013, Antitumor activity of TAK-285, an investigational, non-pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model, *J. Cancer*, 4(7), 557–565.

- Nurhayati, S. dan Lusiyanti, Y., 2014, Apoptosis dan respon biologik sel sebagai faktor prognosa radioterapi kanker, *Buletin Alara*, 7(3), 57-66.
- Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M.G., and Varmus, H., 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, *PLoS Med.*, 2(3), 0225–0235.
- Pongajow, N. T., Juliandri, J., dan Hastiawan, I., 2017, Penentuan geometri dan karakteristik ikatan senyawa kompleks ni (ii)-dibutilditiokarbamat dengan metode density functional theory, *Indones. J. Appl. Sci.*, 7(2), 33-36.
- Rajagopal, K., Arumugasamy, P., and Byran, G., 2019, *In-silico* drug design, ADMET screening, MM-GBSA binding free energy of some chalcone substituted 9-anilinoacridines as HER2 inhibitors for breast cancer, *Int. J. Comput. Theor. Chem.*, 7(1), 6-13.
- Ramachandran, K. I., and Namboori, K., 2008, Computational chemistry and molecular modeling principles and applications, Springer Verlag, Berlin
- Rastini, M. B. O., Giantari, N. K. M., Adnyani, K. D., dan Laksmiani, N. P. L., 2019, Molecular docking aktivitas antikanker dari kuersetin terhadap kanker payudara secara *in silico*, *J. Kim*, 13(2), 180-184.
- Sahu, N. K., Sharna, M. C., Mourya, V. and Kohli, D. V., 2012, QSAR study of some substituted 4-quinolinyl and 9-acridinyl hydrazones as antimalarial agents, *Acta. Pol. Pharm.*, 69, 1153-1165.
- Sanachai, K., Aiebchun, T., Mahalapbutr, P., Seetaha, S., Tabtimmai, L., Maitarad, P., Xenikakis, L., Geronikaki, A., Choowongkomon, K., and Rungrotmongkol, T., 2021, Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives, *RSC Med. Chem.*, 12(3), 430-438.
- Sawatdichaikul, O., Hannongbua, S., Sangma, C., Wolschann, P., and Choowongkomon, K., 2012, *In silico* screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database, *J. Mol. Model.*, 18(3), 1241-1254.
- Soliman, A. M., Alqahtani, A. S., and Ghorab, M., 2019, Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers, *J. Enzyme Inhib. Med. Chem.*, 34(1), 1030–1040.
- Suma, A. A. T., Wahyuningsih, T. D., dan Mustofa, M., 2019, Efficient synthesis of chloro chalcones under ultrasound irradiation, their anticancer activities and molecular docking studies, *Rasayan J. Chem.*, 12(2), 502-510.

- Suma, A. A. T., Wahyuningsih, T. D., dan Mustofa, M., 2019, Synthesis, cytotoxicity evaluation and molecular docking study of N-phenylpyrazoline derivatives, *Indones. J. Chem.*, 19(4), 1081-1090.
- Suwito, H., Pudjiastuti, P., Fanani, M. Z., Kimata-Arigo, Y., Katahira, R., Kawakami, T., Fujiwara, T., Hase, T., Sirat, H.M., and Puspaningsih, N. N. T., 2014, Design and synthesis of chalcone derivatives as inhibitors of the Ferredoxin—Ferredoxin-NADP⁺ reductase interaction of *Plasmodium falciparum*: pursuing new antimalarial agents, *Molecules*, 19(12), 21473-21488.
- Syam, S., Abdelwahab, S. I., Al-Mamary, M. A., and Mohan, S., 2012, Synthesis of chalcones with anticancer activities, *Molecules*, 17(6), 6179-6195.
- Takagi, S., Hayashi, A., and Ohta, Y., 2009, HER2 and HER3 cooperatively regulate tumor cell growth and determine sensitivity to the HER kinase inhibitor TAK-285, *Cancer Res.*, 69(2 Suppl), pp. 3155.
- Tobias, J. S., and Hochhauser, D., 2014, *Cancer and its management*, John Wiley & Sons, New York.
- Trott, O., and Olson, A. J., 2010, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.*, 31(2), 455-461.
- Vázquez-Vuelvas, O. F., Enríquez-Figueroa, R. A., García-Ortega, H., Flores-Alamo, M., and Pineda-Contreras, A., 2015, Crystal structure of the chalcone (E)-3-(furan-2-yl)-1-phenylprop-2-en-1-one, *Acta Cryst.*, E71(2), 161-164.
- Wanita, D., dan Sanjaya, I. G. M., 2020, Studi komputatif jalur sintesis asam elagat dari asam galat, *Unesa Journal of Chemistry*, 9(1), 83-90.
- Wong, H. L., Bendayan, R., Rauth, A. M., Xue, H. Y., Babakhanian, K., and Wu, X. Y., 2006, A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system, *J. Pharmacol. Exp. Ther.*, 317(3), 1372-1381.
- Wu, J., Liao, M., Gordon, J., Zhu, Q., Yu, S., Bulychev, A., and Xia, C., 2009, TAK-285, a novel HER2/EGFR inhibitor, penetrates the CNS in rats with an intact blood brain barrier (BBB), *Cancer Res*, 69(24 Suppl), pp. 5098.
- Wulandari, F., Utami, W., Rohana, E., dan Prabhata, W.R., 2021, Efikasi terapi epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) pada kanker paru, *Generics: J. Res. Pharm.*, 1(1), 25-33.

- Yang, E. B., Guo, Y. J., Zhang, K., Chen, Y. Z., and Mack, P., 2001, Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives, *Biochim. Biophys. Acta*, 1550(2), 144-152.
- Yim-Im, W., Sawatdichaikul, O., Semsri, S., Horata, N., Mokmak, W., Tongsimma, S., Suksamrarn, A., and Choowongkomon, K., 2014, Computational analyses of curcuminoid analogs against kinase domain of HER2, *BMC bioinf.*, 15(1), 1-13.
- Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., and Eck, M. J., 2007, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity, *Cancer Cell*, 11, 217–227.
- Zhang, F., Liu, B., Liu, G., Zhang, Y., Wang, J., and Wang, S., 2018, Substructure-activity relationship studies on antibody recognition for phenylurea compounds using competitive immunoassay and computational chemistry, *Sci. Rep.*, 8(1), 1-8.
- Zhao, M., Wang, L., Zheng, L., Zhang, M., Qiu, C., Zhang, Y., Du, D., and Niu, B., 2017, 2D-QSAR and 3D-QSAR analyses for EGFR inhibitors, *BioMed. Res. Int.*, 2017, 1-11.